Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 2/20 | 0.42 |
| ▸ | CTSK | P43235 | 6/20 | 0.42 |
| ▸ | CTSB | P07858 | 4/20 | 0.42 |
| ▸ | CTSS | P25774 | 3/20 | 0.42 |
| ▸ | CTSL | P07711 | 4/20 | 0.41 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.41 |
| ▸ | PREP | P48147 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26089697 | 1.00 | CCR1 (0.42) | CCR1CTSKCTSBCTSSCTSL | |
| SCHEMBL29648912 | 0.91 | CTSK (0.42) | CCR1CTSKCTSBCTSSCTSL | |
| SCHEMBL21051197 | 0.90 | P2RX7 (0.43) | CCR1CTSKCTSBCTSL | |
| SCHEMBL21051196 | 0.90 | P2RX7 (0.43) | CCR1CTSKCTSBCTSL | |
| SCHEMBL21051198 | 0.90 | P2RX7 (0.43) | CCR1CTSKCTSBCTSL | |
| SCHEMBL30801709 | 0.86 | CTSB (0.47) | CCR1CTSKCTSBCTSSCTSL | |
| SCHEMBL19839889 | 0.82 | CCKBR (0.39) | CCR1CTSKCTSBCTSLCAPN1 | |
| SCHEMBL19839886 | 0.82 | CCKBR (0.39) | CCR1CTSKCTSBCTSLCAPN1 | |
| SCHEMBL15937145 | 0.78 | CTSL (0.47) | CCR1CTSKCTSBCTSSCTSL | |
| SCHEMBL26426398 | 0.76 | MEN1 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230131402-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | APTINYX INC (US) | 2023-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230131402-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | CCR1 2835/4885CTSK 4137/4885CTSB 4429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.